Aera Therapeutics
Company Type: Therapeutics
Main focus: Protein nanoparticles (PNP)
Company stage: Pre-clinical
Diseases: Multiple malignancies, including solid tumours
Genome-editing tool: Licensed therapeutic enzyme platform based on the discovery of novel, compact, and programmable gene-editing enzymes
Funding stage: Series B
Location: Cambridge, Massachusetts, USA
Website: https://aeratx.com
Pipeline: Not disclosed
Partners:
Aera Therapeutics is an R&D company leveraging its proprietary protein nanoparticle (PNP) delivery platform. PNPs are derived from retroelements that self-assemble to form capsid-like structures, which can package and transfer nucleic acid cargo. This platform can deliver a variety of cargos including siRNAs and CRISPR/Cas-based platforms regardless of the payload size, and thus holds potential for the development of potent genetic therapeutics.